The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to BurstPublished by: GlobalData Published: Jun. 7, 2012 - 4 Pages Table of Contents
AbstractThe Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to BurstSummary GlobalData's analysis alert The Rheumatoid Arthritis Community is Swelling with Anticipation as its Research Pipeline Begins to Burst”, analyzes the current pipeline for rheumatoid arthritis drug therapeutics. In addition to the anticipated upcoming approval of Pfizer’s tofacitinib, the pipeline has other entities waiting in the wings. Tofacitinib conquers the troublesome formulation issue as it is administered in oral doses, but other compounds are in development in oral form as well. Tofacitinib also tackles the JAK pathway which current RA therapies do not target, and there are other kinase inhibitors in the development pipeline. Also, there is the possibility of a DNA vaccine which will minimize early symptoms of RA. Finally, we look at a new potential pathway to target in order to inhibit inflammation and joint destruction for people suffering from RA. Scope
Get full details about this report >> |
|
|
|
About MarketResearch.com
|
||

